Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm - Wikidata - wikimedia - TriplyDB

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

http://www.wikidata.org/entity/Q28077186

about

Role of the Pharmacist for Improving Self-care and Outcomes in Heart Failure.Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure.

P2860

Q39148915-82DE946C-2880-4359-BA85-004078BA300E Q41297700-A025EEBE-F1C0-4C49-9146-66EF61DF46ED

P2860

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

http://www.wikidata.org/entity/Q28077186

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

@ast

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

@en

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

@nl

type

label

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

@ast

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

@en

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

@nl

prefLabel

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

@ast

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

@en

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

@nl

P1433

Q28077186-88BA0077-033F-423E-9917-D23F4BC947F0

P1476

Q28077186-D5F88557-3F08-4679-BB7D-CBB7F5C0D1B3

P2093

Q28077186-449FF8DE-15EE-47CA-AA32-66398F960A35

Q28077186-5F918C38-A9E8-4097-80A4-C9788C43452D

Q28077186-9C0FCE3B-EF39-4EFB-8224-A5A2E7F56987

Q28077186-D0AA72BD-BA6C-43A5-922D-A10E7985EEC1

Q28077186-FAFF264A-4652-4B9C-88A4-71AB02D626B8

P275

Q28077186-700AAC12-E607-4CB1-967F-61E3C19FC10A

P2860

Q28077186-004EC8F7-E13E-44DD-BB70-0AA053318EE2

Q28077186-024D5981-4128-4FC3-9932-920A876A6018

Q28077186-03CF9EA6-A9C3-4680-8E8B-59E3FF28E977

Q28077186-0403B259-F43A-4BE2-9B7E-2526A78FB86E

Q28077186-079E12E5-5E07-45A8-9D69-094C582E6870

Q28077186-07C4DF6B-EA69-47B1-88A5-47ED34393560

Q28077186-08768A1C-1901-4379-A4F6-A0094B3F0B4E

Q28077186-09067327-51E1-43B1-BF81-5C6137108F79

Q28077186-099B00BD-036E-4EF9-8BC6-0420BDC5FC6E

Q28077186-0C5A5A7C-AB85-4E04-8FAF-E2D711E9B736

P304

Q28077186-F6DCF9FB-EFEA-433E-8D41-696227BD9A14

P31

Q28077186-D19B2B17-9CCE-4A81-A1C4-EF7ED4C59550

Q28077186-D240DA3D-46F3-4C60-A5A5-05D1FF737740

P356

Q28077186-5F1453DF-0AA5-4BBF-92E2-7EBDD33A4C45

P407

Q28077186-349BF7B8-5940-483C-97AF-50C19F5F7871

P433

Q28077186-03F7E0F9-708D-4E3E-971A-8D11F54A4E21

P478

Q28077186-79DC4AC5-23EC-49A0-859C-F6F3C3C641AD

P5008

Q28077186-0B236D10-F8CE-4873-A123-1E87024D6579

P577

Q28077186-456A268B-D296-4729-A695-6868DF618E23

Q28077186-695F1726-3185-4BD5-9EC1-D4DAC1A0DC87

P698

Q28077186-C8022CFD-2B79-4819-A343-18F936D14920

P921

Q28077186-ACA589B2-F50D-4521-A38F-D119BE7A8448

Q28077186-F1E5BC9F-73E7-40C8-AB1F-6ADE1EDD55B3

Q28077186-FC01D6A9-F24B-472C-8B56-ABEB05747506

P932

Q28077186-204C69E5-8FE2-45EE-831E-78B09240206A

P356

P1433

British Journal of Pharmacology

P1476

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

@en

P2093

Brodie L Loudon

http://www.w3.org/2001/XMLSchema#string

Hannah Noordali

http://www.w3.org/2001/XMLSchema#string

Melanie Madhani

http://www.w3.org/2001/XMLSchema#string

Michael P Frenneaux

http://www.w3.org/2001/XMLSchema#string

Nicholas D Gollop

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Left Ventricular Assist Devices: A Rapidly Evolving Alternative to Transplant

The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

Impaired oxidation of debrisoquine in patients with perhexiline neuropathy

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

P304

1911-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BPH.13480

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

173

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26993743

http://www.w3.org/2001/XMLSchema#string

P921

inorganic compound

heterocyclic compound

P932

4882493

http://www.w3.org/2001/XMLSchema#string